HER2 positive bilateral metachronous primary breast carcinoma: A case report

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Desantis CE, Fedewa SA, Goding SA, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. Ca A Cancer Journal for Clinicians. 2016;66:31. doi:10.3322/caac.21320.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205. doi:10.1016/S0140-6736(16)32616-2.
   PubMed Web of Science ®Google Scholar
• Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29:149–56. doi:10.1200/JCO.2010.28.6450.
   PubMed Web of Science ®Google Scholar
• Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, McLaughlin R, Newell J, Kerin MJ. Bilateral breast cancer: Analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011;126:131–40. doi:10.1007/s10549-010-1057-y.
   PubMed Web of Science ®Google Scholar
• Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat. 2015;153:277–83. doi:10.1007/s10549-015-3538-5.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang BN. Bilateral primary breast cancer: a report of 217 cases. Zhonghua Zhong Liu Za Zhi. 2004;26:756–8. doi:10.3760/j.issn:0253-3766.2004.12.015.
   PubMedGoogle Scholar
• Robbins GF, Berg JW. Bilateral Primary Breast Cancer; a Prospective Clinicopathological Study. Cancer. 1964;17:1501–27. doi:10.1002/1097-0142(196412)17:12%3c1501::AID-CNCR2820171202%3e3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Kan X. Clinicopathology of breast cancer [M]. Beijing: Peking Union Medical College Press, 1993:98–102.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Version 2. 2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
   Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27:1999–2006. doi:10.1200/JCO.2008.19.6618.
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124–30. doi:10.1200/JCO.2008.21.4437.
   PubMed Web of Science ®Google Scholar
• Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15:799–809. doi:10.1634/theoncologist.2009-0029.
   PubMed Web of Science ®Google Scholar
• Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fatima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:976–83. doi:10.1200/JCO.2008.21.6531.
   PubMed Web of Science ®Google Scholar
• Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer. 2011;30:327–35. doi:10.5732/cjc.010.10507.
   PubMedGoogle Scholar
• Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803–14. doi:10.1038/onc.2008.432.
   PubMed Web of Science ®Google Scholar
• Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23:1436–41. doi:10.1093/annonc/mdr474.
   PubMed Web of Science ®Google Scholar
• Bian L, Jiang ZF, Wang T, Song JJ, Guo YF, Zhang HQ, Zhang SH, Wu SK, Song ST. Efficacy and prognostic analysis of retreatment with trastuzumab-based therapy after multi-line targeted therapy resistance in HER2-positive metastatic breast cancer. Zhonghua Yi Xue Za Zhi. 2013;93:48–52. doi:10.3760/cma.j.issn.0376-2491.2013.01.015.
   PubMedGoogle Scholar